Evidence map›Paper›PMID 25033457›Full record

ArticleEpigenetics2014

Aberrant signature methylome by DNMT1 hot spot mutation in hereditary sensory and autonomic neuropathy 1E.

Zhifu Sun, Yanhong Wu, Tamas Ordog, Saurabh Baheti, Jinfu Nie, Xiaohui Duan, Kaori Hojo, Jean-Pierre Kocher, Peter J Dyck, Christopher J Klein

Open access · bronzeAbstract read
In one paragraph

Article in Epigenetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Blood DNA methylation as a potential biomarker of dementia: A systematic review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2018
    Pooled it
  2. Review
  3. Functional and Epigenomic Consequences ofInternational journal of molecular sciences · 2026
    Article
  4. Article
  5. Review
  6. Expanding Upon Genomics in Rare Diseases: Epigenomic Insights.International journal of molecular sciences · 2024
    Review
  7. Article
  8. Article
  9. Review
  10. Differential expression of mMolecular neurobiology · 2023
    Article
  11. Article
  12. Article
  13. Review
  14. DNMT1 maintains metabolic fitness of adipocytes through acting as an epigenetic safeguard of mitochondrial dynamics.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Zhifu SunDivision of Biomedical Statistics and Informatics; Mayo Clinic; Rochester, MN USA; Epigenomics Translational Program; Mayo Clinic Center for Individualized Medicine; Rochester, MN USA; Bioinformatics Program; Mayo Clinic Center for Individualized Medicine; Rochester, MN USA.
Yanhong WuDepartment of Laboratory Medicine and Pathology; Mayo Clinic; Rochester, MN USA.
Tamas OrdogEpigenomics Translational Program; Mayo Clinic Center for Individualized Medicine; Rochester, MN USA; Department of Physiology and Biomedical Engineering; Mayo Clinic; Rochester, MN USA.
Saurabh BahetiDivision of Biomedical Statistics and Informatics; Mayo Clinic; Rochester, MN USA.
Jinfu NieDivision of Biomedical Statistics and Informatics; Mayo Clinic; Rochester, MN USA.
Xiaohui DuanDepartment of Neurology; Mayo Clinic; Rochester, MN USA.
Kaori HojoHarima Sanatorium; Division of Neuropsychiatry; Hyogo, Japan.
Jean-Pierre KocherDivision of Biomedical Statistics and Informatics; Mayo Clinic; Rochester, MN USA; Bioinformatics Program; Mayo Clinic Center for Individualized Medicine; Rochester, MN USA.
Peter J DyckDepartment of Neurology; Mayo Clinic; Rochester, MN USA.
Christopher J KleinDepartment of Laboratory Medicine and Pathology; Mayo Clinic; Rochester, MN USA; Department of Neurology; Mayo Clinic; Rochester, MN USA; Department of Medical Genetics; Mayo Clinic; Rochester, MN USA.
Mayo Clinic in Florida · USWinnMed · USUniversity of Minnesota Rochester · USMayo Clinic · USMoscow Research and Clinical Center for Neuropsychiatry · RU

Funding

Interstitial Cells of Cajal in Diabetic GastropathyR01DK058185 · NIDDK · UNIVERSITY OF NEVADA RENO · PI ORDOG, TAMAS · 2002 to 2020
$5.2M
Identification of Genetic Causes of Hereditary Sensory and Autonomic NeuropathiesK08NS065007 · NINDS · MAYO CLINIC ROCHESTER · PI KLEIN, CHRISTOPHER · 2009 to 2013
$855k
NIDDK NIH HHS R01 DK058185NINDS NIH HHS K08 NS065007
6 · The paper itself

Abstract

DNA methyltransferase 1 (DNMT1) is essential for DNA methylation, gene regulation and chromatin stability. We previously discovered DNMT1 mutations cause hereditary sensory and autonomic neuropathy type 1 with dementia and hearing loss (HSAN1E; OMIM 614116). HSAN1E is the first adult-onset neurodegenerative disorder caused by a defect in a methyltransferase gene. HSAN1E patients appear clinically normal until young adulthood, then begin developing the characteristic symptoms involving central and peripheral nervous systems. Some HSAN1E patients also develop narcolepsy and it has recently been suggested that HSAN1E is allelic to autosomal dominant cerebellar ataxia, deafness, with narcolepsy (ADCA-DN; OMIM 604121), which is also caused by mutations in DNMT1. A hotspot mutation Y495C within the targeting sequence domain of DNMT1 has been identified among HSAN1E patients. The mutant DNMT1 protein shows premature degradation and reduced DNA methyltransferase activity. Herein, we investigate genome-wide DNA methylation at single-base resolution through whole-genome bisulfite sequencing of germline DNA in 3 pairs of HSAN1E patients and their gender- and age-matched siblings. Over 1 billion 75-bp single-end reads were generated for each sample. In the 3 affected siblings, overall methylation loss was consistently found in all chromosomes with X and 18 being most affected. Paired sample analysis identified 564,218 differentially methylated CpG sites (DMCs; P<0.05), of which 300 134 were intergenic and 264 084 genic CpGs. Hypomethylation was predominant in both genic and intergenic regions, including promoters, exons, most CpG islands, L1, L2, Alu, and satellite repeats and simple repeat sequences. In some CpG islands, hypermethylated CpGs outnumbered hypomethylated CpGs. In 201 imprinted genes, there were more DMCs than in non-imprinted genes and most were hypomethylated. Differentially methylated region (DMR) analysis identified 5649 hypomethylated and 1872 hypermethylated regions. Importantly, pathway analysis revealed 1693 genes associated with the identified DMRs were highly associated in diverse neurological disorders and NAD+/NADH metabolism pathways is implicated in the pathogenesis. Our results provide novel insights into the epigenetic mechanism of neurodegeneration arising from a hotspot DNMT1 mutation and reveal pathways potentially important in a broad category of neurological and psychological disorders.

Indexed as

DNA MethylationChild, PreschoolChromosomes, Human, Pair 18Chromosomes, Human, XCpG IslandsDNA (Cytosine-5-)-Methyltransferase 1DNA (Cytosine-5-)-MethyltransferasesGenes, MitochondrialGenomic ImprintingHereditary Sensory and Autonomic NeuropathiesHistonesHumansMutationNADProtein Processing, Post-TranslationalSequence Analysis, DNADNA (Cytosine-5-)-Methyltransferase 1DNA (Cytosine-5-)-MethyltransferasesDNMT1 protein, humanHistonesNADDNA methylationHSAN1EneurodegenerationOMIM 604121OMIM 614116whole genome bisulfite sequencing

Identifiers

PMID25033457
PMCPMC4164503
OpenAlexW2068888619

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.